ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Chimerix Inc

Chimerix Inc (CMRX)

3.62
0.23
(6.78%)
Closed January 06 4:00PM
3.65
0.03
(0.83%)
After Hours: 7:39PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.65
Bid
3.45
Ask
4.00
Volume
1,289,167
3.30 Day's Range 3.64
0.75 52 Week Range 3.69
Market Cap
Previous Close
3.39
Open
3.45
Last Trade
1
@
3.61
Last Trade Time
Financial Volume
$ 4,445,513
VWAP
3.4484
Average Volume (3m)
4,293,086
Shares Outstanding
89,936,053
Dividend Yield
-
PE Ratio
-3.97
Earnings Per Share (EPS)
-0.91
Revenue
324k
Net Profit
-82.1M

About Chimerix Inc

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Chimerix Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CMRX. The last closing price for Chimerix was $3.39. Over the last year, Chimerix shares have traded in a share price range of $ 0.75 to $ 3.69.

Chimerix currently has 89,936,053 shares outstanding. The market capitalization of Chimerix is $304.88 million. Chimerix has a price to earnings ratio (PE ratio) of -3.97.

CMRX Latest News

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...

Small Cap Soars On FDA Submission Plans

A healthcare company based out of North Carolina is turning heads so far during Tuesday’s session after the company announced that it plans to submit its Dordaviprone for To read the full...

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement...

Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3510.60606060613.33.693.218350343.4469268CS
42.78319.5402298850.873.690.82133644342.65328902CS
122.7796319.3474264710.87043.690.842930862.59475824CS
262.78319.5402298850.873.690.7521844482.41617481CS
522.685278.2383419690.9653.690.7512721882.23693822CS
156-2.79-43.32298136656.447.020.7515432582.26142672CS
2601.5573.80952380952.111.56960.7512249883.1107826CS

CMRX - Frequently Asked Questions (FAQ)

What is the current Chimerix share price?
The current share price of Chimerix is $ 3.65
How many Chimerix shares are in issue?
Chimerix has 89,936,053 shares in issue
What is the market cap of Chimerix?
The market capitalisation of Chimerix is USD 304.88M
What is the 1 year trading range for Chimerix share price?
Chimerix has traded in the range of $ 0.75 to $ 3.69 during the past year
What is the PE ratio of Chimerix?
The price to earnings ratio of Chimerix is -3.97
What is the cash to sales ratio of Chimerix?
The cash to sales ratio of Chimerix is 1.01k
What is the reporting currency for Chimerix?
Chimerix reports financial results in USD
What is the latest annual turnover for Chimerix?
The latest annual turnover of Chimerix is USD 324k
What is the latest annual profit for Chimerix?
The latest annual profit of Chimerix is USD -82.1M
What is the registered address of Chimerix?
The registered address for Chimerix is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Chimerix website address?
The website address for Chimerix is www.chimerix.com
Which industry sector does Chimerix operate in?
Chimerix operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FCUVFocus Universal Inc
$ 0.9499
(174.93%)
260.93M
NITON2OFF Inc
$ 2.6306
(145.85%)
358.28M
CRNCCerence Inc
$ 19.33
(143.76%)
161.8M
KITTNauticus Robotics Inc
$ 3.8249
(140.56%)
104.8M
ACONAclarion Inc
$ 0.2984
(110.14%)
305.64M
HWHHWH International Inc
$ 0.4621
(-28.80%)
7.43M
SMSTDefiance Daily Target 2x Short MSTR ETF
$ 5.69
(-26.30%)
24.77M
RAINRain Enhancement Technologies Holdco Inc
$ 5.59
(-23.42%)
161.15k
PTLEPTL Ltd
$ 9.35
(-23.30%)
1.04M
NXUNXU Inc
$ 0.725868
(-22.78%)
7.59M
NITON2OFF Inc
$ 2.6306
(145.85%)
358.28M
TGLTreasure Global Inc
$ 0.382
(101.58%)
337.5M
ACONAclarion Inc
$ 0.2984
(110.14%)
305.64M
FCUVFocus Universal Inc
$ 0.9499
(174.93%)
260.93M
NVDANVIDIA Corporation
$ 144.47
(4.45%)
230.01M

CMRX Discussion

View Posts
glenn1919 glenn1919 7 days ago
CMRX................https://stockcharts.com/h-sc/ui?s=CMRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 1 week ago
cmrx...................https://stockcharts.com/h-sc/ui?s=cmrx&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 2 weeks ago
cmrx..................https://stockcharts.com/h-sc/ui?s=cmrx&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
bikaver bikaver 2 weeks ago
CMRX.....bought in @ 2.93.....could see another leg up!
πŸ‘οΈ0
glenn1919 glenn1919 3 weeks ago
CMRX.........................................https://stockcharts.com/h-sc/ui?s=CMRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 4 weeks ago
CMRX..............https://stockcharts.com/h-sc/ui?s=CMRX&p=W&b=5&g=0&id=p86431144783
🏦 1 ✅️ 1
Zardiw Zardiw 4 weeks ago
$CMRX - Gain: 217% #DDAmanda Video Analysis - #1 Stock Screener / Scanner

#DDAmanda Christmas Special Signup:

https://ddamanda.com/SignUpXMAS.php

Questions/Support: 760 702-2009 - Hans@DDAmanda.com



Z
πŸ‘οΈ0
dablitz dablitz 4 weeks ago
Congrat's to those those who had a good day here today.
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
CMRX: Another article about it ---
https://finance.yahoo.com/news/why-cancer-focused-chimerix-stock-143934294.html
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
CMRX...All out in the $3.10 range...🥳Beauty flip...from $2.02 range...

georgie18

Member Level
Re: georgie18 post# 667358

Tuesday, December 10, 2024 9:45:48 AM

Post#
667376
of 667379
CMRX...$2.71...🥳...Volume...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 386753

Tuesday, December 10, 2024 8:14:24 AM

Post#
386761
of 386773
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie18

Member Level
Re: None

Monday, December 09, 2024 4:21:32 PM

Post#
386753
of 386753
CMRX...$2.02...🥳...DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
CMRX...$2.71...🥳...Volume...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 386753

Tuesday, December 10, 2024 8:14:24 AM

Post#
386761
of 386773
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie18

Member Level
Re: None

Monday, December 09, 2024 4:21:32 PM

Post#
386753
of 386753
CMRX...$2.02...🥳...DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie18

Member Level
Re: None

Monday, December 09, 2024 4:21:32 PM

Post#
386753
of 386753
CMRX...$2.02...🥳...DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
πŸ‘οΈ0
glenn1919 glenn1919 4 weeks ago
CMRX.............................https://stockcharts.com/h-sc/ui?s=CRMX&p=W&b=5&g=0&id=p86431144783
👍️ 1 💲 1
Invest-in-America Invest-in-America 4 weeks ago
CMRX: Soaring!!! Likely $3-4 bucks in the Post-M!!!
πŸ‘οΈ0
glenn1919 glenn1919 4 weeks ago
CMRX.......................https://stockcharts.com/h-sc/ui?s=CMRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
CMRX...$2.22...🥳...

georgie18

Member Level
Re: None

Monday, December 09, 2024 4:21:32 PM

Post#
386753
of 386753
CMRX...$2.02...🥳...DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
CMRX...$2.02...🥳...DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
👍 1
pzottkpz pzottkpz 2 months ago
⏰⏰⏰⏰⏰⏰⏰⏰⏰⏰

can this hold a buck if markets correct
or will they have to do something to maintain listing

💲CMRX
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
CMRX new 52 week low
πŸ‘οΈ0
mick mick 1 year ago
GBIM
Globelmmune Inc (CE)
0.0002
0.00 (0.00%)
Volume:
πŸ‘οΈ0
mick mick 1 year ago
GBIM
Globelmmune Inc (CE)
0.0002
0.00 (0.00%)
Volume:
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CMRX new 52 low
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CMRX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CMRX new 52 week low
πŸ‘οΈ0
kzivann kzivann 2 years ago
Thanks, saw that but neglected to post news.

CMRX
πŸ‘οΈ0
db7 db7 2 years ago
https://www.businesswire.com/news/home/20221110005658/en/
πŸ‘οΈ0
kzivann kzivann 2 years ago
More good news.

CMRX
πŸ‘οΈ0
kzivann kzivann 2 years ago
News looks good.

CMRX
πŸ‘οΈ0
kzivann kzivann 2 years ago
Nice news. Got some.

CMRX
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
WEEEEEEEEE
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
Monday fun here CMRX$ WOW! Monkey pox vaccine
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
$5 coming
πŸ‘οΈ0
mcjodie mcjodie 2 years ago
Looking good
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$
πŸ‘οΈ0
db7 db7 2 years ago
from the EBS earnings call transcript:

"
Unidentified Analyst

This is Nick on for Boris. So I just have a quick question about Chimerix and TEMBEXA. So previously, the -- right pretty much right after you guys announced this acquisition of TEMBEXA, they said that the BARDA contract was likely to take place within the next couple of weeks or months, and now it's pushed back. And I just wanted to know if you guys had any reasoning behind this or any information as to why it's been pushed back, especially with monkeypox and now being declared a public health emergency, you kind of think that it may be pushed forward, but it seems to be just pushed back a little bit more.

Bob Kramer

Yes. Thanks, Nick, for the question. Thanks for joining the call. So a couple of comments. As I commented on my prepared remarks, the HSR process and the waiting period for this expired last Friday. So now that, I think, gives BARDA and Chimerix kind of the green light to finalize the BARDA procurement agreement, which then gives us the clear path to closing the transaction and moving forward.

I wouldn't read anything into the perhaps perceived delay in getting the contract awarded. Obviously, BARDA is looking at this very carefully and they are aware that our interest in acquiring the product from Chimerix. So I think, again, there's momentum to get this done, and we're anxious to get done as well

"
πŸ‘οΈ0
db7 db7 2 years ago
my hope is that the BARDA negotiation is to 'upsize' the original contract that was discussed(?)
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$$$$$$$$ WOOHOOOOOO
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$ $5 TARGET
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$Surfin USA
πŸ‘οΈ0
db7 db7 2 years ago
interesting if we get BARDA announcement this week; per last extension due 'soon'
πŸ‘οΈ0
Trend22 Trend22 2 years ago
CMRX - Nice news and nice pre market!
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX SIGA $$$$$$$$$$$$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
Now we’re moving WOOHOOOOOO CMRX$$$$$$$$$$$$$$SIGA
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX SIGA Upchurch HI-DEAS 2 $$$$$$$$$$$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
CMRX $10 TARGET PRICE WOOHOOOOOO
πŸ‘οΈ0
weedtrader420 weedtrader420 3 years ago
BUYING BUYING BUYING
πŸ‘οΈ0
weedtrader420 weedtrader420 3 years ago
CMRX$
πŸ‘οΈ0
weedtrader420 weedtrader420 3 years ago
Monkeypox is spreading all over America
πŸ‘οΈ0